Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma

Abstract

BackgroundAs the crosstalk between metabolism and antitumor immunity continues to be unraveled, we aim to develop a prognostic gene signature that integrates lipid metabolism and immune features for patients with lung adenocarcinoma (LUAD).MethodsFirst, differentially expressed genes (DEGs) related to lipid metabolism in LUAD were detected, and subgroups of LUAD patients were identified via the unsupervised clustering method. Based on lipid metabolism and immune-related DEGs, variables were determined by the univariate Cox and LASSO regression, and a prognostic signature was established. The prognostic value of the signature was evaluated by the Kaplan–Meier method, time-dependent ROC, and univariate and multivariate analyses. Five independent GEO datasets were employed for external validation. Gene set enrichment analysis (GSEA), gene set variation analysis (GSVA), and immune infiltration analysis were performed to investigate the underlying mechanisms. The sensitivity to common chemotherapeutic drugs was estimated based on the GDSC database. Finally, we selected PSMC1 involved in the signature, which has not been reported in LUAD, for further experimental validation.ResultsLUAD patients with different lipid metabolism patterns exhibited significant differences in overall survival and immune infiltration levels. The prognostic signature incorporated 10 genes and stratified patients into high- and low-risk groups by median value splitting. The areas under the ROC curves were 0.69 (1-year), 0.72 (3-year), 0.74 (5-year), and 0.74 (10-year). The Kaplan–Meier survival analysis revealed a significantly poorer overall survival in the high-risk group in the TCGA cohort (p < 0.001). In addition, both univariate and multivariate Cox regression analyses indicated that the prognostic model was the individual factor affecting the overall survival of LUAD patients. Through GSEA and GSVA, we found that tumor progression and inflammatory and immune-related pathways were enriched in the high-risk group. Additionally, patients with high-risk scores showed higher sensitivity to chemotherapeutic drugs. The in vitro experiments further confirmed that PSMC1 could promote the proliferation and migration of LUAD cells.ConclusionsWe developed and validated a novel signature incorporating both lipid metabolism and immune-related genes for all-stage LUAD patients. This signature can be applied not only for survival prediction but also for guiding personalized chemotherapy and immunotherapy regimens.

Investigation of the Proteasome 26S Subunit, ATPase Family Genes as Potential Prognostic Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma

“…A previous study reported that PSMC1 promotes the proliferation and migration of lung adenocarcinoma cells and is related to poor prognosis in patients with lung adenocarcinoma. 29 and metastasis of colorectal cancer and its high expression correlates with poor prognosis in colorectal cancer. 30 Consistent with studies in other tumor types, high expression levels of PSMCs correlated with poor prognosis and shorter survival in HCC.…”

Overexpression of PFKP in liver hepatocellular carcinoma: study of prognostic effects and discovery of potential drug sensitivity

“…Further comprehensive investigations are warranted to elucidate the precise underlying factors supporting this speculative interpretation Yang T et al found in vitro experiments that FLT3 expression was reduced in LIHC. They further analyzed its prognostic characteristics by plotting survival curves and found that the FLT3 high expression group had better survival outcomes than the low expression group [19] . Quizartinib is an inhibitor of FMS-like tyrosine kinase 3 (FLT3).…”

A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma

“…Previous researches have suggested that mast cells are an essential source of VEGF, which facilitates the proliferation and angiogenesis of tumors ( 47 , 48 ). Nevertheless, recent studies have characterized the heterogeneity of mast cells and proved that the subpopulation of CD103+ mast cells display a stronger expression of molecules associated with antigen presentation, which include CD80, ICAM-1 as well as MHC-II-like molecules, which effectively activate CD4+ T cells in turn ( 49 ). The proportion of CD4 memory resting T cell infiltration decreased significantly with increasing patient risk.…”